Roche Abandons AKT Prostate Cancer Asset

Roche Abandons AKT Prostate Cancer Asset

Source: 
BioSpace
snippet: 

Roche is dropping its investigational AKT inhibitor ipatasertib, which was being assessed in a Phase III trial for castration-resistant prostate cancer, the company revealed Thursday in its 2022 full-year financial report.